EBV VCA IgG blood test

This test detects IgG antibodies directed against the viral capsid antigen (VCA) of the Epstein-Barr virus in your blood. VCA IgG antibodies appear early during an EBV infection, typically within the first few weeks after exposure. Unlike VCA IgM antibodies, which usually fade within a few months, VCA IgG antibodies then persist indefinitely. The test reports whether these antibodies are present and, depending on the laboratory, how high the level is. A high VCA IgG level on its own says little about whether an infection is active: that becomes clearer only when it is read together with other EBV markers.

VCA IgG testing is a commonly used component of the EBV antibody panel. Because VCA IgG antibodies persist for life, a positive result confirms exposure to the Epstein-Barr virus (EBV) at some point. The value becomes most meaningful when read alongside other markers. VCA IgM may point to a recent or acute infection, while Epstein-Barr nuclear antigen (EBNA) IgG develops only weeks to months later. Early antigen (EA) IgG antibodies can add further context. Together, these antibodies to EBV help a healthcare professional estimate the stage of infection. This can be relevant when evaluating symptoms such as prolonged fatigue. When symptoms resemble mononucleosis, a CMV IgG test may also be relevant, since cytomegalovirus can produce a similar picture.

Testing may be considered when investigating symptoms consistent with infectious mononucleosis, such as fatigue, sore throat, and swollen lymph nodes. It can also be used to map EBV exposure status as part of a broader evaluation. A healthcare professional can help determine whether an EBV VCA IgG test is informative in your situation.